KR950000149A - 오메프라졸 주사용 제제 - Google Patents
오메프라졸 주사용 제제 Download PDFInfo
- Publication number
- KR950000149A KR950000149A KR1019930009791A KR930009791A KR950000149A KR 950000149 A KR950000149 A KR 950000149A KR 1019930009791 A KR1019930009791 A KR 1019930009791A KR 930009791 A KR930009791 A KR 930009791A KR 950000149 A KR950000149 A KR 950000149A
- Authority
- KR
- South Korea
- Prior art keywords
- omeprazole
- buffer
- methylglucamine
- injection
- present
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- SUBDBMMJDZJVOS-UHFFFAOYSA-N 5-methoxy-2-{[(4-methoxy-3,5-dimethylpyridin-2-yl)methyl]sulfinyl}-1H-benzimidazole Chemical compound N=1C2=CC(OC)=CC=C2NC=1S(=O)CC1=NC=C(C)C(OC)=C1C SUBDBMMJDZJVOS-UHFFFAOYSA-N 0.000 title claims abstract 10
- 229960000381 omeprazole Drugs 0.000 title claims abstract 9
- 238000002360 preparation method Methods 0.000 title claims abstract 4
- MBBZMMPHUWSWHV-BDVNFPICSA-N N-methylglucamine Chemical compound CNC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO MBBZMMPHUWSWHV-BDVNFPICSA-N 0.000 claims abstract 4
- 239000003814 drug Substances 0.000 claims abstract 4
- 238000002347 injection Methods 0.000 claims abstract 4
- 239000007924 injection Substances 0.000 claims abstract 4
- 150000003839 salts Chemical class 0.000 claims abstract 4
- 239000000872 buffer Substances 0.000 claims abstract 3
- 239000007853 buffer solution Substances 0.000 claims abstract 2
- ZPWVASYFFYYZEW-UHFFFAOYSA-L dipotassium hydrogen phosphate Chemical compound [K+].[K+].OP([O-])([O-])=O ZPWVASYFFYYZEW-UHFFFAOYSA-L 0.000 claims abstract 2
- 229910000396 dipotassium phosphate Inorganic materials 0.000 claims abstract 2
- 235000019797 dipotassium phosphate Nutrition 0.000 claims abstract 2
- 229940079593 drug Drugs 0.000 claims abstract 2
- 239000008363 phosphate buffer Substances 0.000 claims abstract 2
- 239000000243 solution Substances 0.000 claims abstract 2
- LENZDBCJOHFCAS-UHFFFAOYSA-N tris Chemical compound OCC(N)(CO)CO LENZDBCJOHFCAS-UHFFFAOYSA-N 0.000 claims abstract 2
- 239000000654 additive Substances 0.000 claims 1
- 239000012153 distilled water Substances 0.000 claims 1
- 238000009472 formulation Methods 0.000 claims 1
- 238000000034 method Methods 0.000 claims 1
- 239000000203 mixture Substances 0.000 claims 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims 1
- 239000004480 active ingredient Substances 0.000 abstract 1
- 230000000087 stabilizing effect Effects 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/13—Amines
- A61K31/133—Amines having hydroxy groups, e.g. sphingosine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/66—Phosphorus compounds
- A61K31/665—Phosphorus compounds having oxygen as a ring hetero atom, e.g. fosfomycin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Dermatology (AREA)
- Medicinal Preparation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
본 발명은 오메프라졸 및 그의 염의 안정화된 수성 주사용 제제에 관한 것이다.
본 발명은, 오메프라졸 또는 비경구투여 가능한 그의 염을 약물로서 함유하는 용액의 pH를 N-메틸글루카민 또는 완충액계로서 2-아미노-2-하이드록시메틸-1,3-프로판디올 완충용액, 또는 N-메틸글루카민+포타슘 하이드로겐포스페이트 완충액 등을 사용하여 pH 8.5-9.5의 범위로 조절하는 제조하는 것을 특징으로 하는 안정화된 오메프라졸의 주사용 제제를 제공한다.
본 발명에 의한 오메프라졸의 주사용 약제는 활성성분의 안정화 효과가 매우 뛰어난 오메프라졸의 주사용 약제이다.
Description
본 내용은 요부공개 건이므로 전문내용을 수록하지 않았음
Claims (2)
- 약물로서 오메프라졸 또는 비경구투여 가능한 오메프라졸 염, 및 제약학적으로 혀용되는 통상의 주사용 첨가제를 주사용 증류수에 용해시키고, 이 용액을 N-메틸글루카민 또는 완충용액으로 pH 8.5-9.5로 조절하여 통상의 방법으로 주사제용 용기에 충전한 오메프라졸 및 그 염의 주사용 제제.
- 제1항에 있어서, 완충용액이 2-아미노-2-하이드록시메틸-1,3-프로판디올 완충용액, 또는 N-메틸글루카민+포타슘 하이드로겐포스페이트 완충용액임을 특징으로 하는 오메프라졸 및 그 염의 주사용 제제.※ 참고사항 : 최초출원 내용에 의하여 공개하는 것임.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| KR1019930009791A KR960008233B1 (ko) | 1993-06-01 | 1993-06-01 | 오메프라졸 주사용 제제 |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| KR1019930009791A KR960008233B1 (ko) | 1993-06-01 | 1993-06-01 | 오메프라졸 주사용 제제 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| KR950000149A true KR950000149A (ko) | 1995-01-03 |
| KR960008233B1 KR960008233B1 (ko) | 1996-06-21 |
Family
ID=19356585
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| KR1019930009791A Expired - Lifetime KR960008233B1 (ko) | 1993-06-01 | 1993-06-01 | 오메프라졸 주사용 제제 |
Country Status (1)
| Country | Link |
|---|---|
| KR (1) | KR960008233B1 (ko) |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN114159396A (zh) * | 2021-10-21 | 2022-03-11 | 济南同路医药科技发展有限公司 | 一种注射用艾司奥美拉唑钠冻干制剂及其制备方法 |
Families Citing this family (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR100900647B1 (ko) * | 2008-01-31 | 2009-06-02 | 김기호 | 이중냉각구조의 다면균일 순환급속 냉각장치 |
-
1993
- 1993-06-01 KR KR1019930009791A patent/KR960008233B1/ko not_active Expired - Lifetime
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN114159396A (zh) * | 2021-10-21 | 2022-03-11 | 济南同路医药科技发展有限公司 | 一种注射用艾司奥美拉唑钠冻干制剂及其制备方法 |
Also Published As
| Publication number | Publication date |
|---|---|
| KR960008233B1 (ko) | 1996-06-21 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| KR890015745A (ko) | 수용액으로 존재하는 피록시캄의 제약 조성물 및 그의 제조방법 | |
| KR890006644A (ko) | 결정성 β-락탐 수화물 | |
| KR880009020A (ko) | 신규 치료법 | |
| BR9307700A (pt) | Formulação para estabilizar uma composição enzimática lìquida, composição enzimática lìquida estabilizada, método para a preparação de uma composição enzimática lìquida estabilizada e método para estabilizar uma composição enzimática lìquida | |
| BR9510452A (pt) | Composição farmacêutica e aquosa estéril para a administração parenteral processos para limitar o potencial de crescimento microbiano em composição farmacêutica estéril para a administração parenteral para produzir anestesia em um animal de sangue quente e para aperfeiçoar o tempo de administração e/ou o tempo entre as trocas de conjuntos | |
| BR0112417A (pt) | Composições farmacêuticas contendo composto dds | |
| DE69840106D1 (de) | Formulierungen für amylin peptidagonisten mit insulin | |
| KR900018098A (ko) | 피리돈 카르복실산과 항균제 | |
| KR940008681A (ko) | 디클로페낙 염용 비경구 용액 | |
| KR880000093A (ko) | 신규의 국소처리용 약제학적 조성물 | |
| KR970061270A (ko) | 히토성장호르몬을 함유하는 의약제제 | |
| MX173607B (es) | Antitranspirante cristalino y metodo para su preparacion | |
| RU94046143A (ru) | Фармацевтическая композиция для лечения глаукомы | |
| KR910000703A (ko) | 테트라졸 자극성 아미노산 수용체의 길항물질 | |
| KR880013572A (ko) | 인슐린 및 인슐린 유도체의 혼합결정체, 이의 제조방법, 이를 함유하는 약제 및 이의 용도 | |
| KR920007571A (ko) | 영양학적 조성물 및 이의 제조방법 | |
| KR880007060A (ko) | 제약 조성물 | |
| KR900006330A (ko) | 피롤로[3,2-e]피라졸로[1,5-a]피리미딘 유도체 및 이를 함유하는 약제 | |
| KR950000149A (ko) | 오메프라졸 주사용 제제 | |
| CA2244389A1 (en) | Cilansetron pharmaceutical preparation stabilized against racemization | |
| KR890012960A (ko) | 결정성 β-락탐 용매화물 | |
| KR930023338A (ko) | 데포우 제제 | |
| KR890015741A (ko) | 상승작용을 갖는 수의학적 조성물 및 그의 제조방법 | |
| PT97164A (pt) | Processo para a estabilizacao de uma preparacao que contenham o composto 4-etil-2-hidroxi-imino-5-nitro-3-hexenamida e de composicoes farmaceuticas que o contenham | |
| KR870700024A (ko) | 약, 비타민 또는 왁진의 근육내 주사용 제제 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| A201 | Request for examination | ||
| PA0109 | Patent application |
Patent event code: PA01091R01D Comment text: Patent Application Patent event date: 19930601 |
|
| PA0201 | Request for examination |
Patent event code: PA02012R01D Patent event date: 19930601 Comment text: Request for Examination of Application |
|
| PG1501 | Laying open of application | ||
| G160 | Decision to publish patent application | ||
| PG1605 | Publication of application before grant of patent |
Comment text: Decision on Publication of Application Patent event code: PG16051S01I Patent event date: 19960528 |
|
| O035 | Opposition [patent]: request for opposition | ||
| PO0301 | Opposition |
Comment text: Request for Opposition Patent event code: PO03011R01D Patent event date: 19960821 |
|
| PC1902 | Submission of document of abandonment before decision of registration | ||
| SUBM | Surrender of laid-open application requested |